Last checked at 29 Jun 2023 07:00
Unless otherwise defined herein, the capitalised defined terms used in this announcement have the same meaning as those used in the Company's announcements released on 27 June 2023 unless otherwise defined herein.
29 June 2023
Physiomics plc
("PYC" or the "Company")
Completion of Fundraise to raise gross proceeds of £380,477
Physiomics plc (AIM:PYC) is pleased to announce, further to its announcements of 27 June 2023, the completion of the Subscription and the WRAP Retail Offer, as well as the placing of an additional 2,000,000 Ordinary Shares on the same terms as the Placing (together, the "Fundraise"). The Fundraise, which is conditional on Admission, raises gross proceeds of, in aggregate, £380,477 through the issue of a total of 38,047,700 new Ordinary Shares (the "Fundraise Shares").
Enlarged Placing
Further to the Company's announcement of 27 June 2023, the Company is pleased to confirm that it has placed an additional 2,000,000 new Ordinary Shares on the same terms as the Placing, through Hybridan LLP, taking the total placing to 34,500,000 new Ordinary Shares raising gross proceeds of, in aggregate, £345,000.
WRAP Retail Offer
The WRAP Retail Offer, which closed at 16:30 BST yesterday, has raised gross proceeds of £25,477 through the issue of 2,547,700 new Ordinary Shares to existing retail shareholders in the United Kingdom.
Director Subscriptions
Further to the Company's announcement of 27 June 2023, the Company can confirm that Dr James ('Jim') Millen (Executive Chairman and CEO) and Dr Christophe Chassagnole (COO) have each subscribed for £5,000 of new Ordinary Shares at the Placing price pursuant to a direct subscription with the Company and accordingly will each be issued 500,000 new Ordinary Shares. On Admission, Dr Millen and Dr Chassagnole will be interested in, in aggregate, 1,884,393 and 1,102,723 Ordinary Shares respectively, representing 1.39% and 0.81% of the Company's then enlarged issued share capital.
Use of Proceeds
In order to further develop its business and accelerate growth, the Company targeted a raise of around £300,000 with the intention of using the net proceeds of the Fundraise towards activities including:
· Further expansion and diversification of its client base;
· Expansion of its consulting business into the adjacent area of pharmaceutical biostatistics services; and
· Exploration of opportunities around its personalised oncology software offering.
Admission and Total Voting Rights
Application has been made for the 38,047,700 Fundraise Shares to be admitted to trading on AIM, which is expected to take effect and dealings to commence at 8.00 a.m. on or around 3 July 2023 ("Admission").
Following Admission, the Company will have 135,472,478 Ordinary Shares in issue. Since the Company currently holds no shares in treasury, the total number of voting rights in the Company will therefore be 135,472,478. These figures may therefore be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.
Enquiries:
Physiomics plc
Dr Jim Millen, CEO +44 (0)1865 784 980
Hybridan LLP (Broker) +44 (0) 203 764 2341
Claire Louise Noyce
Strand Hanson Ltd (NOMAD) +44 (0)20 7409 3494
James Dance
James Bellman
Winterflood Retail Access Platform WRAP@winterflood.com
Alex Skrine, Head of Electronic Trading +44 (0) 20 3100 0009
Haris Khawaja, Corporate Finance +44 (0) 20 3100 0189
The Company's LEI is 213800A71DSZ6ABMTQ91
PDMR Notification Forms
1. | Details of the person discharging managerial responsibilities / person closely associated | |||||
a) | Name | Jim Millen | ||||
2. | Reason for the Notification | |||||
a) | Position/status | Executive Chairman and CEO | ||||
b) | Initial notification/amendment | Initial notification | ||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | Physiomics plc | ||||
b) | LEI | 213800A71DSZ6ABMTQ91 | ||||
4. | Details of the transaction(s):section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv)each place where transactions have been conducted | |||||
a) | Description of the Financial instrument, type of instrument | Physiomics plc new Ordinary Shares | ||||
Identification code | ISIN: GB00BDR6W943 | |||||
b) | Nature of the Transaction | A subscription for new ordinary shares in the Company | ||||
c) | Price(s) and volume(s) | Dr Jim Millen
| ||||
d) | Aggregated information - Aggregated volume
- Price
|
500,000 £0.01 | ||||
e) | Date of the transaction | 28 June 2023 | ||||
f) | Place of the transaction | Off market transaction | ||||
1. | Details of the person discharging managerial responsibilities / person closely associated | |||||
a) | Name | Christophe Chassagnole | ||||
2. | Reason for the Notification | |||||
a) | Position/status | Executive Director, COO | ||||
b) | Initial notification/amendment | Initial notification | ||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | Physiomics plc | ||||
b) | LEI | 213800A71DSZ6ABMTQ91 | ||||
4. | Details of the transaction(s):section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv)each place where transactions have been conducted | |||||
a) | Description of the Financial instrument, type of instrument | Physiomics plc new Ordinary Shares | ||||
Identification code | ISIN: GB00BDR6W943 | |||||
b) | Nature of the Transaction | A subscription for new ordinary shares in the Company | ||||
c) | Price(s) and volume(s) | Dr Christophe Chassagnole
| ||||
d) | Aggregated information - Aggregated volume
- Price
|
500,000 £0.01 | ||||
e) | Date of the transaction | 28 June 2023 | ||||
f) | Place of the transaction | Off market transaction | ||||
Notes to Editor
About Physiomics
Physiomics plc (AIM: PYC) is an oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions. The Company's Virtual Tumour™ technology uses computer modelling to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Physiomics' technologies have been confirmed by over 100 projects, involving over 50 targets and 75 drugs, and has worked with clients such as Merck KGaA, Astellas, Merck & Co and Bicycle Therapeutics.
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 as it forms part of United Kingdom domestic law by virtue of the European Union (Withdrawal) Act 2018, as amended by virtue of the Market Abuse (Amendment) (EU Exit) Regulations 2019.